Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Research And Development Expense of $44.49 million for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +11.3% in Research And Development Expense from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Tonix Pharmaceuticals Holding Corp.'s Research And Development Expense has grown by 7,513.6%.
- Historical annual values: Fiscal year 2025: $44.49 million | Fiscal year 2024: $39.97 million | Fiscal year 2023: $86.66 million | Fiscal year 2022: $81.88 million | Fiscal year 2021: $68.84 million | Fiscal year 2020: $36.16 million | Fiscal year 2019: $18.19 million | Fiscal year 2018: $17.56 million | Fiscal year 2017: $13.34 million | Fiscal year 2016: $28.53 million | Fiscal year 2015: $35.50 million | Fiscal year 2014: $18.62 million | Fiscal year 2013: $4.65 million | Fiscal year 2012: $2.58 million | Fiscal year 2011: $1.16 million | Fiscal year 2010: $584.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: